X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

TOT BIOPHARM and LEE’S PHARM Signed an Exclusive Licensing Agreement on Monoclonal Antibody Drug

Yuvraj_pawp by Yuvraj_pawp
5th January 2017
in Asia, News

TOT BIOPHARM Co Ltd. and LEE’S PHARMACEUTICAL HOLDINGS LIMITED jointly announced that LEE’S PHARM, through its wholly-owned subsidiary Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited has acquired the exclusive license of TAB014, the monoclonal antibody drug developed and manufactured by TOT BIOPHARM, within China.

TAB014 is a new antibody product that can be used to treat wet age-related macular degeneration (wAMD) and other eye diseases.

According to the Agreement, LEE’S PHARM will receive the exclusive rights to carry out the clinical and commercial development of TAB014 in China (including mainland China, Hong Kong and Macau), and make the upfront payment, milestone payment and after-launch sales commission to TOT BIOPHARM. At the same time, LEE’S PHARM will pay the costs incurred during the processes of clinical development, regulatory submission and product commercialization in the licensed territory. The early stage of this cooperation will focus on the clinical development of TAB014 in the treatment of wAMD, in which both parties will share the study results and data.


“Through this cooperation, we can put greater emphasis on the oncology field and specialize in the R&D and manufacture of monoclonal antibody/antibody-drug conjugate, oncolytic virus products and specialty anti-cancer drugs,” said Gloria Huang, General Manager of TOT BIOPHARM. “LEE’S PHARM’s achievements in international connection are widely known, and its development in the ophthalmic field has been outstanding in recent years. We are truly pleased to cooperate with LEE’S PHARM because it will benefit both parties.

We believe that the cooperation will lead to the success of TAB014 and present a new treatment option for patients.” Dr. Xiaoyi Li, CEO of LEE’S PHARM expressed, “We are honored to work with TOT BIOPHARM on the development of TAB014. This is the second drug for treating retinopathy after Resolvine ER, which was developed through the cooperation of our Company with the U.S.-based Kato Pharmaceuticals. The cooperation with TOT BIOPHARM has further enriched our ophthalmic product line and again demonstrated our determination to develop ophthalmic drugs.”

As there are over two million people in China suffering from wAMD, and existing treatment options are rather limited and pricey, the potential market value of this product will be more than a billion of RMB.


About wet age-related macular degeneration (wAMD)

Wet age-related macular degeneration, which is caused by genetic diseases, age-related changes, inflammatory diseases, as well as other retinopathies, may lead to blindness if not treated early. Studies show that the level of the vascular endothelial growth factor (VEGF) was significantly higher in patients with wAMD and other eye diseases, such as diabetic macular edema (DME) and secondary macular edema (ME) of retinal vein occlusion (RVO). Since 2005, some ophthalmologists began to use anti-VEGF drugs to treat eye diseases and have confirmed their efficacy. At present, the anti-VEGF drugs of wAMD approved by the FDA and EU include Ranibizumab (Trade name: Lucentis®) and Aflibercept (Trade name: Eylea®), while the anti-VEGF drugs approved by CFDA include Ranibizumab and Conbercept (Trade name: Lang Mu®).

Tags: Asia Pacific
Previous Post

Senhwa Biosciences gets Orphan Drug Designation from US FDA for CX-4945

Next Post

Adaptive Biotechnologies, Amgen partner to develop sequencing-based ALL assay

Related Posts

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

GSK Commits £1 Billion To Combat Infections In Poor Nations

27th June 2022
Next Post

Adaptive Biotechnologies, Amgen partner to develop sequencing-based ALL assay

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In